Drug Trial Radar · NCT05126277
Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis
Last checked: Nov 20, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
452
Actual
Start
Jul 14, 2022
Primary completion
Sep 21, 2027
Study completion Feb 4, 2031
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Nov 19, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial will evaluate efficacy, safety, and tolerability of subcutaneous (s.c.) ianalumab given every 4 weeks (q4w) or every 12 weeks (q12w) compared to placebo, in combination with SoC, in adult participants with active LN
Conditions
- Lupus Nephritis
Interventions
ianalumab s.c. q4wDrug
ianalumab s.c. q4w in addition to SoC
ianalumab s.c. q12wDrug
ianalumab s.c. q12w in addition to SoC
placebo s.c.Drug
placebo s.c. q4w in addition to SoC
Primary outcomes
What the sponsor says the trial is designed to measure.
- Frequency and percentage of participants achieving stable Complete Renal Response (CRR)Time frame: Week 72
Locations
145 sites in 27 countries. Site status is shown where the registry gives one.
University Of Alabama
Birmingham, Alabama
Advanced Medical Research
La Palma, California
University of California Irvine
Orange, California
School Of Medicine
Sacromento, California
University of California San Diego
San Deigo, California
Kaiser Permanente
San Diego, California
Mayo Clinic Jacksonville
Jacksonville, Florida
University Of Miami
Miami, Florida
Emory University School of Medicine
Atlanta, Georgia
Fides Clinical Research
Atlanta, Georgia
Parris and Associates Rheumatology
Lawrenceville, Georgia
Accurate Clinical Research
Lake Charles, Louisiana
UMC New Orleans
New Orleans, Louisiana
Wayne State University
Detroit, Michigan
Univ of Nevada School of Med
Las Vegas, Nevada
NY Nephrology
Clifton Park, New York
Hospital for Special Surgery
New York, New York
Northwell Health
New York, New York
Circuit Clinical
Orchard Park, New York
University Of Cincinnati
Cincinnati, Ohio
Univ of Pennsylvania Medical Center
Philadelphia, Pennsylvania
Precision Comprehensive Research
Colleyville, Texas
Univof Texas Southwestern Med Cntr
Dallas, Texas
Uni of Texas Health Science Center
San Antonio, Texas
Uni Wisconsin School Med Pub Health
Madison, Wisconsin
Novartis Investigative Site
Caba, Argentina
Novartis Investigative Site
CABA, Argentina
Novartis Investigative Site
San Miguel de Tucumán, Argentina
Novartis Investigative Site
CABA, Buenos Aires, Argentina
Novartis Investigative Site
La Plata, Buenos Aires, Argentina
Novartis Investigative Site
Salvador, Brazil
Novartis Investigative Site
Vitória, Espírito Santo, Brazil
Novartis Investigative Site
Salvador, Estado de Bahia, Brazil
Novartis Investigative Site
Belo Horizonte, Minas Gerais, Brazil
Novartis Investigative Site
Juiz de Fora, Minas Gerais, Brazil
Novartis Investigative Site
Recife, Pernambuco, Brazil
Novartis Investigative Site
Porto Alegre, Rio Grande do Sul, Brazil
Novartis Investigative Site
Porto Alegre, Rio Grande do Sul, Brazil
Novartis Investigative Site
Santo André, São Paulo, Brazil
Novartis Investigative Site
Calgary, Alberta, Canada
Showing 40 of 145 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.